MedTrace Logo

A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis

NCT04110873 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-10-01

No results posted yet for this study

Summary

Primary Objective:

To evaluate the activity of Antroquinonol in patients with atopic dermatitis.

Secondary Objective:

To assess the mechanism and cytokines change of Antroquinonol in patients with atopic dermatitis.

Exploratory Objective:

To explore potential relationships between Antroquinonol exposure and safety and efficacy endpoints.

Conditions

Interventions

DRUG

Antroquinonol Capsule 50mg

patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks

DRUG

Antroquinonol Capsule 100mg

patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks

DRUG

Placebo oral capsule

patients will receive placebo per day (QD) on Day 1 for 12 weeks

Sponsors & Collaborators

  • Golden Biotechnology Corporation

    collaborator INDUSTRY

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • Wei C- C, M.D. · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-27
Primary Completion
2019-06-25
Completion
2019-06-25

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110873 on ClinicalTrials.gov